Growth in Personalized Medicine to Drive Alliances Between Diagnostics and Pharmaceutical Industries, According to PricewaterhouseCoopers
... adoption of new diagnostic technologies in the guidelines of important clinical communities, which should accelerate their market adoption. Agendia's mammaprint
(a DNA-based test for evaluating an individual's risk of breast cancer spreading to other sites) is an example of a new diagnostic tool to help person...
Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
...e joining Agendia at such a pivotal and exciting
time in the company's development," said Dr. Bender. "Their FDA cleared
breast cancer prognostic test mammaprint
clearly shows that Agendia is
becoming an important diagnostic provider for the management of breast
cancer. The company's promising oncology pipeline...
MammaPrint(R) Breast Cancer Test Shown To Be Powerful Tool for Prognosis Prediction in Postmenopausal Breast Cancer Patients
...der age breast cancer patients as well.
To date, mammaprint
has received two clearances from the Food and Drug...e first clearance in February of this
year cleared mammaprint
for safety and effectiveness under the In Vitro
Di...oston, USA between 1985 and 1997
were subjected to mammaprint
gene expression analysis. MammaPrint, having a
Agendia's MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
...wing shipping of tumor biopsies at ambient
temperature, greatly facilitating the logistical process of sample
"We are very pleased to make mammaprint
widely available to U.S.
patients and their physicians," said Bernhard Sixt, chief executive officer
and co-founder of Agendia. "We believe it will pl...
FDA Clears Breast Cancer Specific Molecular Prognostic Test
...cular test that profiles genetic activity.
test uses the latest in molecular technology to pr...es located in the tumor. Prognostic tests like the mammaprint
can measure the activity of these genes, and thus ...en on the market since 2005.
"Clearance of the mammaprint
test marks a step forward in the initiative to bri...
MammaPrint in Medical Technology
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
HUNTINGTON BEACH, California and AMSTERDAM, June 23 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced the
inclusion of its breast cancer recurrence test MammaPrint
in St. Gallen's
2009 International Expert Consensus on the primary therapy of early breast
/C O R R E C T I O N -- Agendia B.V./
Agendia's Breast Cancer Recurrence Test mammaprint
International St. Gallen Expert Consen...the inclusion
of its breast cancer recurrence test mammaprint
in St. Gallen's 2009
International Expert Consensu...not useful in clinical decision making. Currently, mammaprint
is the only
breast cancer recurrence assay availab...
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
...t(R), was used to differentiate between patients at high and low
risk for recurrence.
HER2+ patients are commonly identified as high risk, yet mammaprint
able to identify a low risk subgroup of HER2+ patients, who subsequently
experienced a 10 year disease-free survival of close to 90 percent even i...
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
...omplete response (pCR)
rate and the results of the mammaprint
"Physicians are increasingly supportive of mammaprint
practice because they believe it provi...hese findings suggest tumors with a poor
signature are sensitive to chemotherapy.
Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
is the first 'in vitro diagnostic multivariate ind... early metastasis
risk. In planning treatment, the mammaprint
test result provides a doctor
with a clear rationa...nical information and pathology tests.
tests are conducted in Agendia's CLIA-certified se...
Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
...cer Consultation Group (NABON).
The inclusion of mammaprint
in CBO's updated clinical practice
guidelines acknowledge the prognostic power of mammaprint
in general and
highlight its ability to identify s...ing additional knowledge.
"We are delighted that mammaprint
has been included in the CBO
guidelines," said Ber...
MammaPrint in Biological Technology
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
HUNTINGTON BEACH, California, and AMSTERDAM, February 18 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced that
a study demonstrating the direct predictive ability of its breast cancer
recurrence test, MammaPrint(R), has been published in Breast Cancer Re...
Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
...ading product, MammaPrint(R), is commercialized globally to
aid physicians in making informed treatment decisions for breast cancer
patients. In 2007, mammaprint
became the first in vitro diagnostic
multivariate index assay (IVDMIA) cleared by the FDA. FDA clearance requires
clinical and analytical validation a...
Agendia Opens CLIA-Registered U.S. Genomics Laboratory
...ment, and pathologist Dr.
Chynel Henning, Laboratory Director.
"Our new genomics lab's capacity will allow us to meet the increasing
demand for mammaprint
across the United States and give physicians and
patients optimal test result turnaround and unmatched service and support,"
noted Jan Groen, Ph.D., C...
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
... A. M. Glas
is the first 'in vitro diagnostic multivariate ind... early metastasis risk. In
planning treatment, the mammaprint
test results provide doctors with a clear
information and pathology tests.
tests are conducted in Agendia's CLIA-accredited s...
Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
Comparison of mammaprint
and TargetPrint Results with Clinical Parameters
i...2 March 2009
The 70-gene mammaprint
Prognosis Signature for Optimal Risk
Stratificatio...2 March 2009
The 70-gene mammaprint
Signature Is Predictive for Chemotherapy Benefit
Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
...euwenhoek Hospital (NKI-AVL). The NKI-AVL
provides better guidance for decisions regarding a...s in the MINDACT trial NKI-AVL is
already offering mammaprint
to patients and will continue to do so. In
future, however, NKI-AVL will also make mammaprint
available to patients who
fall outside MINDACT's i...
Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
... the right partner for the
successful expansion of mammaprint
and CupPrint into these additional
European market...e valuable information provided by these tests."
is a clinically proven, highly accurate gene expre...y worldwide.
"Having followed the development of mammaprint
and CupPrint, we are
excited about the opportunity...
Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
"We are honored that the value of mammaprint
has been recognized at a
governmental level for it...ients will benefit from personalized
was among four healthcare innovations awarded by D...e
suffering from cancer, and new technologies like mammaprint
the way oncologists are treating this...
MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
..."These studies demonstrate the clinical utility of mammaprint
helping physicians make more informed decisions...cipated in both studies. "Prognostic tests such as mammaprint
ushered in a new era in personalized medicine...ive trial to assess the
clinical implementation of mammaprint
in 15 community hospitals in The
Netherlands. Of 4...